<DOC>
	<DOCNO>NCT00515892</DOCNO>
	<brief_summary>RATIONALE : The CAT-8015 immunotoxin bind tumor cell kill without harm normal cell . This may effective treatment Non-Hodgkin 's lymphoma ( NHL ) respond chemotherapy , surgery radiation therapy . PURPOSE : Phase 1 dose escalation study determine maximum tolerate dose CAT-8015 immunotoxin treat patient Non-Hodgkin 's lymphoma respond treatment .</brief_summary>
	<brief_title>Safety Study CAT-8015 Immunoxin Patients With NHL With Advance Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>INCLUSION CRITERIA : DISEASE CHARACTERISTICS : Confirmed diagnosis Bcell nonHodgkin 's lymphoma Measurable disease Evidence CD22positive malignancy follow criterion , &gt; 30 % malignant cell disease site CD22+ FACS analysis , &gt; 15 % malignant cell disease site must react antiCD22 immunohistochemistry Patients indolent subtypes CD22+ Bcell nonHodgkin 's lymphoma , include , limited mantle cell lymphoma , follicular lymphoma Waldenström 's macroglobulinemia , eligible stage IIIIV . Patients must fail least two course prior standard chemotherapy and/or biologic therapy ( e.g . Rituxan ) . Patients progressive mantle cell lymphoma may eligible fail one prior standard therapeutic regimen . PATIENTS CHARACTERISTICS Performance Status ECOG 02 Life Expectancy Life expectancy le 6 month , assess principal investigator Other Patients cancer meet eligibility criterion le 5 year disease free survival consider casebycase basis Must able understand sign inform consent Female male patient must agree use approve method contraception study History bone marrow transplant Documented ongoing central nervous system involvement malignant disease ( history CNS involvement exclusion criterion ) Pregnant breastfeed female Patients whose plasma contain either significant level antibody CAT8015 measure ELISA , antibody neutralizes bind CAT8015 CD22 measure competition ELISA . HIV positive serology ( due increase risk severe infection unknown interaction CAT8015 antiretroviral drug ) Hepatitis B surface antigen positive Uncontrolled , symptomatic , intercurrent illness include limited : infection require systemic antibiotic , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement Hepatic function : serum transaminase ( either ALT AST ) bilirubin ≥ Grade 2 , unless bilirubin due Gilbert 's disease Renal function : Serum creatinine clearance ≤ 60mL/min estimate CockroftGault formula Hematologic function : The ANC &lt; 1000/cmm , platelet count &lt; 50,000/cmm , cytopenia judge investigator due underlying disease ( i.e . potentially reversible antineoplastic therapy ) . A patient exclude pancytopenia ≥ Grade 3 , erythropoietin dependence , due disease , base result bone marrow study Baseline coagulopathy &gt; Grade 3 unless due anticoagulant therapy . Pulmonary function : Patients &lt; 50 % predict forced expiratory volume ( FEV1 ) &lt; 50 % predict diffusing capacity carbon monoxide ( DLCO ) , correct hemoglobin concentration alveolar volume . Note : Patient prior history pulmonary illness require PFTs . FEV1 assess bronchodilator therapy . Recent prior therapy : Cytotoxic chemotherapy , corticosteroid ( except stable dos prednisone ) , whole body electron beam radiation therapy , hormonal , biologic standard investigational therapy malignancy 3 week prior entry trial Less equal &lt; 3 month prior monoclonal antibody therapy ( i.e . rituximab ) Patients receive receive radiation therapy le 3 week prior study entry exclude providing volume bone marrow treat less 10 % also patient measurable disease outside radiation port Any history prior pseudomonasexotoxin immunotoxin ( PE ) administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>